Oath Research Testing Rating: Batch Coverage, Lab Partner, and Endotoxin Standard

What drives the testing sub-score

The Oath Research testing rating lands at 9.2 / 10 because five separate inputs converge — and because the inputs are independently verifiable rather than vendor-attested.

The batch count is 451 as of September 2026 in Oath's own public archive. RealPeptidesScores' independent audit (9 May 2026) captures 142 of those COAs and still characterizes the cadence as 'roughly four times the next-best vendor we audited' — about 36.3 COAs per month, with 109 of 142 falling within the last 90 days at audit time. The growth rate is observable, not historical.

The coverage is every-batch. Not lot-level, not spot-check, not 'representative samples.' Every batch that ships has a COA in the public archive, indexed by name, batch number, and CAS number. This is rare in the research-peptide category; peptiderecon's head-to-head identifies it as 'the gold standard in testing transparency.'

The lab partner is Freedom Diagnostics — an independent commercial laboratory. Freedom Diagnostics serves multiple unrelated vendors and is not exclusive to Oath. The lab has been operating since 2023 per its public statements. None of those facts is self-reported by Oath.

Is Oath Research third-party tested?

Yes. Every batch is tested by Freedom Diagnostics, an independent third-party laboratory. As of September 2026, 451 batches have been tested. Coverage is every-batch (not lot-level, not spot-check), with results published as searchable COAs on the company's primary site.

What lab does Oath Research use?

Freedom Diagnostics — an independent third-party laboratory. Freedom Diagnostics serves multiple unrelated vendors and is not affiliated with Oath beyond the testing relationship. The lab has been operating since 2023 per public statements.

How many batches has Oath Research tested?

451 batches as of September 2026, with the program actively growing month over month. RealPeptidesScores' independent audit puts the cadence at roughly 36.3 COAs per month — about four times the next-best vendor that site audited. The cadence — not just the total — is what distinguishes an actively maintained testing program from a one-time marketing exercise.

What is Oath Research's average purity?

99.64% average purity (trailing 12 months) across the publicly visible batch archive. The individual peptides span a tight range. The eight specific products with captured test data:

• GLP2-T (Tirzepatide) — 99.93% across 8 batches.
• SS-31 — 99.86% across 4 batches.
• Selank — 99.71% across 5 batches.
• BPC-157 — 99.66% across 10 batches (highest test count in the visible subset).
• Tesamorelin + Ipamorelin blend — 99.43% across 6 batches.
• BPC-157 + TB-500 (WOLVERINE blend) — 99.39% across 8 batches.

All listed test dates fall in May 2026. The captured subset is not the complete catalog — Oath's site shows more SKUs than the 2026-05-26 snapshot — but the visible pattern is tight clustering at the high end of the published purity range.

What is USP <85>?

USP <85> is the United States Pharmacopeia compendial test for bacterial endotoxins — the published standard for verifying that a parenteral preparation does not carry endotoxin contamination above defined limits. Oath Research names USP <85> as the endotoxin standard for its testing program, and its archive summary states that endotoxin safety is confirmed by an independent laboratory. The individual certificates publish the purity and identity results and note that other batches of the same product have been endotoxin-tested — so the verifiable fact is the standard Oath states, not a per-batch pass rate this rating has counted. The standard matters because endotoxin contamination is a real risk vector for any injectable preparation, and a vendor that names a specific pharmacopeial standard is making a checkable claim rather than a marketing one — checkable against the standard it names, which is what this rating credits.

What is the Oath Research testing score?

Strong — top band among publicly visible U.S. research-peptide vendors. The inputs that drive this sub-score: more than 400 batches tested, every-batch (not lot-level) coverage, Freedom Diagnostics as third-party lab, USP <85> named as the endotoxin standard, and 99.64% average purity (trailing 12 months). The testing sub-score carries the heaviest weight (40%) in the composite because for a research-peptide vendor, batch-level independent third-party testing is the load-bearing legitimacy fact. Without that layer, every other claim a vendor makes is unauditable.

Why the ceiling is 9.2 and not 10

Our methodology does not assign 10 / 10 to any sub-score where the underlying evidence is younger than two years. Oath's testing program is roughly ten months old at the time of writing. The cadence is high, the methodology is sound, the lab partner is real and independent — but the program has not yet accumulated the multi-year history that would justify a maximum. As the testing archive extends past 24 months of continuous output without methodology drift or lab-partner turnover, the ceiling will lift. The 9.2 is a strong-band reading of evidence that is excellent in depth but recent in span — the honest mid-point between 'compelling now' and 'longitudinally proven.'